Navigation Links
Elective Surgery - the Financial Whipping Boy

The Australian reported last week that patients in several states were made to wait for common elective procedures such as cataract removals// and knee and hip replacements for much longer periods than they used to.

The average wait for a cataract removal has risen from 168 days to 218 days in NSW and from 152 to 176 days in Victoria. Almost one-third of patients in NSW and in the Northern Territory have waited more than a year for knee replacements.

According to health professionals and economists the public hospital system seems to be struggling to cope with the increasing medical demands of their aging population. Surgical waiting lists only prove that public system hospitals are miserably failing to properly manage their busy emergency departments as well as their elective surgery lists.

In surgical waiting lists elective cases usually have to take a back seat. While balancing a hospital budget also, usually emergency surgeries get preference over elective surgeries.

Several states have proposed to remove elective surgery as a responsibility of public hospitals. In November, the Government plans to open a $90 million facility to perform elective surgery on public patients.

In South Australia the government developed two operating theatres on the grounds of the Flinders Medical Centre specifically to perform elective eye operations. The number of elective eye procedures increased from 566 in 1999-00 to 1521 in 2004-05.

. Last year the NSW Government launched plans to revitalize the system by redirecting some elective patients from large hospitals to smaller hospitals as well as the government linked funding for the number of elective procedures each hospital performed. As a result they have become equipped with a series of important performance indicators such as the number of operations hospitals do thereby payment is made for work done rather than waiting list targets.

Private hospitals
'"/>




Page: 1 2

Related medicine news :

1. Doctors Object To Elective Surgery Cuts In New South Wales
2. Australia In Search Of A Better Way to Handle Critically Ill Patients and Balance Elective Surgery
3. Elective surgery should take precedence over bureaucracy, says surgeon
4. Doctors Warned Against Encouraging Elective Caesareans
5. Bypass Heart Surgery Performed Without General Anesthesia
6. Indian Prime Minister has successful Knee Replacement Surgery
7. Surgery made simple
8. Surgery a safety in senility
9. Breast Cancer Surgery Causes Psychological problems
10. Radiofrequency Energy Cooks Tumors Without Surgery
11. Heart Surgery Is Getting Safer for the Old
Post Your Comments:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2